Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.55 |
| ▸ | JAK1 | P23458 | 13/20 | 0.55 |
| ▸ | JAK3 | P52333 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554076 | 0.82 | JAK1 (0.78) | JAK1 | |
| SCHEMBL17867964 | 0.80 | JAK2 (0.86) | JAK2JAK1 | |
| SCHEMBL13535843 | 0.80 | JAK2 (0.62) | JAK2JAK1JAK3 | |
| SCHEMBL13535708 | 0.79 | JAK2 (0.68) | JAK2JAK1JAK3 | |
| SCHEMBL3229522 | 0.77 | JAK2 (0.78) | JAK2JAK3 | |
| SCHEMBL3223801 | 0.74 | JAK2 (0.67) | JAK2JAK3 | |
| SCHEMBL3229281 | 0.74 | JAK2 (0.64) | JAK2JAK3 | |
| SCHEMBL3226193 | 0.74 | JAK2 (0.64) | JAK2JAK1JAK3 | |
| SCHEMBL13535894 | 0.74 | JAK2 (0.69) | JAK2JAK1JAK3 | |
| SCHEMBL3213421 | 0.73 | JAK2 (0.76) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | JAK2 2/4885JAK1 3/4885JAK3 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.